ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0296

Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies

maria Casal-Dominguez1, Iago Pinal Fernandez2, Katherine Pak2, Travis Kinder1, Jon Musai1, Ana Matas-Garcia3, Gloria Garrabou4, Iban aldecoa5, Albert Selva-O´callaghan6, José Milisenda7 and Andrew Mammen8, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, Spain, 4Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, 5Pathology, Neurological Tissue Bank. Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain., Barcelona, 6Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain, Barcelona, 7Hospital Clinic de Barcelona, Barcelona, Spain, 8NIH, Bethesda, MD

Meeting: ACR Convergence 2025

Keywords: Autoantibody(ies), Imaging, immunology, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoimmune inflammatory myopathies (IMs) comprise a diverse group of diseases that primarily affect the muscles and often involve the lungs, skin, and joints. Among them, patients with autoantibodies against aminoacyl-tRNA synthetases develop a distinct clinical entity known as antisynthetase syndrome (ASyS), characterized by inflammatory myopathy, pulmonary fibrosis, arthritis, Raynaud’s phenomenon, and mechanic’s hands. The most common antisynthetase autoantibody, anti-Jo1, targets histidyl-tRNA synthetase (HARS).Recent studies have demonstrated that autoantibodies can penetrate muscle fibers and disrupt the function of their target autoantigens. In ASyS patients, this process induces a distinct transcriptomic profile that recapitulates the effects of pharmacologic inhibition of HARS with histidinol.This study aims to examine the localization of anti-Jo1 antibodies and their cognate antigen, HARS1, in muscle biopsies from anti-Jo1–positive ASyS patients and diseased controls.

Methods: We performed direct immunofluorescence for IgG and HARS1 staining on 10 μm-thick unfixed muscle sections from patients with anti-Jo1 autoantibodies and those with other forms of inflammatory myopathy. Images were acquired using a Leica SP8 high-resolution confocal microscope.

Results: We observed co-aggregation of HARS1 and internalized IgG in muscle biopsies from ASyS patients with anti-Jo1 autoantibodies (Figure 1). This pattern was not detected in samples from patients with other forms of myopathy.

Conclusion: Our data suggest that antibodies from anti-Jo1 patients induce HARS1 aggregation in the cytoplasm of muscle fibers. Notably, similar HARS1 aggregation has been observed in patients with HARS1 mutations and Charcot-Marie-Tooth (CMT) disease. In CMT, this aggregation disrupts HARS1 function, resulting in errors in peptide translation.

Supporting image 1Direct immunofluorescence showing the aggregation of HARS1 and internalized antibodies in a muscle biopsy of a patient with antisynthetase syndrome and anti-Jo1 (HARS1) autoantibodies


Disclosures: m. Casal-Dominguez: None; I. Pinal Fernandez: None; K. Pak: None; T. Kinder: None; J. Musai: None; A. Matas-Garcia: None; G. Garrabou: None; I. aldecoa: None; A. Selva-O´callaghan: None; J. Milisenda: None; A. Mammen: None.

To cite this abstract in AMA style:

Casal-Dominguez m, Pinal Fernandez I, Pak K, Kinder T, Musai J, Matas-Garcia A, Garrabou G, aldecoa I, Selva-O´callaghan A, Milisenda J, Mammen A. Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/aggregation-of-hars1-and-internalized-antibodies-in-muscle-biopsies-of-patients-with-antisynthetase-syndrome-and-anti-jo1hars-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/aggregation-of-hars1-and-internalized-antibodies-in-muscle-biopsies-of-patients-with-antisynthetase-syndrome-and-anti-jo1hars-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology